Anzeige
Mehr »
Donnerstag, 08.01.2026 - Börsentäglich über 12.000 News
Das Wildwest-Silberrevier, das bei 80-Dollar-Silber wichtiger ist denn je!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von FierceBiotech

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
12.11.25Alkermes races to phase 3 after posting another narcolepsy win
12.11.25Bayer bails on Vividion tumor drug as part of early-stage cancer clear-out
12.11.25Metagenomi sheds 25% of workforce, including CEO, to focus on preclinical hemophilia program
11.11.25With Summit leading the pack in PD-1xVEGF bispecifics, Pfizer lays out its own plan to replace Keytruda
11.11.25Neuphoria, reeling from phase 3 trial fail, mulls buyout offer from investor
11.11.25Novo Nordisk shares mixed data behind pivotal heart disease push
11.11.25Neurocrine's depression drug is latest asset from Takeda pact to flunk a phase 2 trial
10.11.25Voyager, Transition Bio set sail on neuro research trek in search for small molecule candidates
10.11.25AI-driven Iambic raises $100M-plus as it looks to advance pipeline, strike more deals
10.11.25Cogent eyes FDA submission for cancer asset after clearing another phase 3 hurdle
10.11.25Merck's PCSK9 pill holds 'significant advantage' with injectable-like cholesterol reductions: analysts
10.11.25AnaptysBio abandons rosnilimab for ulcerative colitis after phase 2 fail
10.11.25Lyell hands over $70M-plus in cash, equity for 'impressive' phase 1-stage colorectal cancer CAR-T
10.11.25Roche reports phase 3 multiple sclerosis wins for BTK inhibitor, succeeding where rivals failed
10.11.25AstraZeneca's $1.3B bet reduces blood pressure by 14 mmHg over 12 weeks in phase 3 win
10.11.25FDA puts Tenaya heart disease gene therapy clinical trial on hold
10.11.25Eli Lilly pens $1.2B pact with Sanegene to better target metabolic RNA meds
08.11.25Pfizer beats out Novo with $10B agreement to buy Metsera
07.11.25Sana, CAMP4 ditch clinical-stage assets for more promising preclinical candidates
07.11.25Patient dies after receiving Intellia's CRISPR therapy
06.11.25FDA reveals second round of 'national priority' voucher winners, including obesity giants Lilly and Novo
06.11.25Cullinan sidelines pair of oncology assets amid expansion into autoimmune R&D
06.11.25Axsome adds AstraZeneca epilepsy candidate to pipeline through Avenue subsidiary acquisition
06.11.25UroGen hands anti-CTLA-4 drug back to Agenus after being unimpressed with phase 1 data
06.11.25Eli Lilly links amylin agonist to 20% weight loss, sparking charge into phase 3